496
Participants
Start Date
December 31, 2011
Primary Completion Date
April 30, 2016
Study Completion Date
April 30, 2016
sorafenib
Patients will receive continuous oral treatment with 800 mg of sorafenib daily (Nexavar, Bayer HealthCare Pharmaceuticals-Onyx Pharmaceuticals). Treatment interruptions and dose reductions (to 400 mg once daily) will be permitted for drug-related adverse effects. At the discretion of the investigator, the dose may be re-escalated to after the resolution of the adverse event.
SIR-Sphere
The first step will check patient eligibility and prepare conditioning by performing selective mesenteric and hepatic angiography (to document the arterial tumor supply and to occlude extrahepatic vessels) and 99mTc-macroaggregated albumin scintigraphy. The second step is RADIOEMBOLIZATION therapy. One to two weeks after patient eligibility and conditioning, treatment is performed with SIR-Sphere (SIRTEX Medical Ltd.,Lane Cove,Australia).
Institut Paoli Calmettes #7, Marseille
CHU Marseille Hôpital La Timone #23, Marseille
Hôpital Côte de Nacre #4, Caen
CHU Dijon Hôpital Bocage #22, Dijon
CHRU Besançon Hôpital Jean Minjoz #21, Besançon
Hôpital Haut Leveque #14, Pessac
Hôpital Saint Eloi #8, Montpellier
CHU Grenoble #5, Grenoble
CHU Saint Etienne Hôpital Nord #17, Saint-Priest-en-Jarez
Hotel Dieu #10, Nantes
CHU Angers #3, Angers
CHU Robert Debré #28, Reims
Hôpital de Brabois #9, Nancy
Hôpital de Hautepierre #18, Strasbourg
Hôpital Edouard Herriot #6, Lyon
Lyon La croix Rousse #27, Lyon
Hôpital Européen Georges Pompidou #13, Paris
CHU Amiens #2, Amiens
CHU Poitiers La Milétrie, Poitiers
Hopital beaujon #1, Clichy
Hôpital Antoine Béclère #29, Clamart
Hôpital Jean Verdier #25, Bondy
Henri Mondor #24, Créteil
Paul Brousse #19, Villejuif
Institut Gustave Roussy #20, Villejuif
Hôpital de L'Archet #11, Nice
Ministry of Health, France
OTHER_GOV
Assistance Publique - Hôpitaux de Paris
OTHER